Press Releases

Date Title View
Toggle Summary Second Sight Medical Products, Inc. Announces $40 Million Rights Offering of Units and Two Year Extension of Warrants (EYESW) Expiration Date
LOS ANGELES , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today
View HTML
Toggle Summary Second Sight Reports Fourth Quarter 2018 Business Update
-- Full Year 2018 net revenue estimated to be in the range of $6.5-$6.9 million -- -- 6 th Orion patient scheduled for implantation at Baylor Medical Center -- LOS ANGELES , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or the “Company”), a
View HTML
Toggle Summary Second Sight to Present at Digital Medicine and Medtech Showcase 2019
LOS ANGELES , Dec. 20, 2018 (GLOBE NEWSWIRE) -- Second Sight Medical Products , Inc. (NASDAQ:EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today
View HTML
Toggle Summary Second Sight Completes $3 million Private Placement of Common Stock with Gregg Williams, Chairman of the Board of Directors
LOS ANGELES , Dec. 14, 2018 (GLOBE NEWSWIRE) -- Second Sight Medical Products , Inc. (NASDAQ:EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today
View HTML
Toggle Summary Second Sight to Present at the 11th Annual LD Micro Main Event Conference in Los Angeles on Wednesday, December 5th
LOS ANGELES , Nov. 27, 2018 (GLOBE NEWSWIRE) -- Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today
View HTML
Toggle Summary Second Sight Reports Third Quarter 2018 Financial Results
Encouraging Interim Results of Orion ® Feasibility Study with Four Subjects Cleared for Home Use LOS ANGELES , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual
View HTML
Toggle Summary Second Sight Announces Final 2019 Medicare Hospital Outpatient Payment Rate for the Argus II Retinal Prosthesis System
LOS ANGELES , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Second Sight Medical Products , Inc. (NASDAQ:EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today
View HTML
Toggle Summary Second Sight to Discuss Third Quarter 2018 Financial Results on November 7, 2018 Conference Call
LOS ANGELES --(BUSINESS WIRE)--Oct. 30, 2018-- Second Sight Medical Products, Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind individuals, will release its 2018 third quarter
View HTML
Toggle Summary Second Sight Completes $4 million Private Placement of Common Stock with Gregg Williams, Chairman of the Board of Directors
LOS ANGELES --(BUSINESS WIRE)--Oct. 22, 2018-- Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind individuals, today
View HTML
Toggle Summary Second Sight Receives $1.6 Million Grant from National Institutes of Health to Support Orion Clinical Development
--Total Grant Amount Up to $6.3 Million Over Five Years-- LOS ANGELES --(BUSINESS WIRE)--Sep. 18, 2018-- Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an
View HTML